Last reviewed · How we verify
Neostigmine Injectable Solution
At a glance
| Generic name | Neostigmine Injectable Solution |
|---|---|
| Also known as | Neostigmine plus Glycopyrrolate, Group B |
| Sponsor | University of California, Irvine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries (PHASE1, PHASE2)
- MgSO4 as Adjuvants to Bupivacaine vs Neostigmine in TAP Block in Cesarean Section (PHASE2, PHASE3)
- Neostigmine Route for Acute Colonic Pseudo Obstruction (PHASE4)
- Effect of Intrathecal Neostigmine on Post-dural Puncture Headache. (PHASE4)
- Intrathecal Neostigmine for Prevention of PDPH (PHASE4)
- Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neostigmine Injectable Solution CI brief — competitive landscape report
- Neostigmine Injectable Solution updates RSS · CI watch RSS
- University of California, Irvine portfolio CI